RSV LID ΔM2-2 Vaccine

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Respiratory Syncytial Virus Infections

Phase 1

Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

CompletedNCT02040831

National Institute of Allergy and Infectious Diseases (NIAID)Respiratory Syncytial Virus Infections

Start: 2014-09-30End: 2015-04-30Updated: 2016-12-21

Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

CompletedNCT02237209

National Institute of Allergy and Infectious Diseases (NIAID)Respiratory Syncytial Virus Infections

Start: 2014-09-30End: 2015-04-30Updated: 2015-10-08

Related Papers

Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in Children

The Journal of Infectious Diseases2018-01-2670 citations